CASE REPORT

Case Report: Anesthetic management for Cesarean section in a parturient with unspecified inherited bleeding disorder [version 2; peer review: 2 approved]

Li Li¹, Jill M. Johnsen², Chau X. Doan¹, Laurent A. Bollag¹

¹Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, WA, 98195, USA
²Department of Medicine - Hematology, University of Washington, Seattle, WA, 98195, USA

Abstract
Neuraxial anesthesia, as the standard of care for Cesarean deliveries, is associated with decreased blood loss. However, parturients with inherited bleeding disorders are at increased risk for epidural hematomas. A small retrospective study has shown that parturients with known factor deficiencies can safely undergo neuraxial anesthesia once the specific factors are replenished. We present a patient who had a considerably increased risk of peripartum bleeding from an unspecified inherited bleeding disorder and was provided a successful neuraxial anesthetic without complications. We discuss the multidisciplinary approach among the surgeons, anesthesiologists, hematologist, and nursing staff to maximize patient safety and comfort.

Keywords
Anesthesia, Spinal, Cesarean section, Parturient, Bleeding disorder

Open Peer Review

Invited Reviewers

<table>
<thead>
<tr>
<th>Version</th>
<th>Invited Reviewers</th>
<th>Report</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>¹</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>²</td>
<td>✔</td>
</tr>
</tbody>
</table>

Any reports and responses or comments on the article can be found at the end of the article.
A 39-year-old G6P3 with an unspecified inherited bleeding disorder presented at 37-6/7 weeks gestational age for a fourth repeat scheduled CD in the setting of fetal macrosomia. The patient had a diagnosis of an unspecified bleeding disorder. Prior to diagnosis, her bleeding history consisted of easy bruising, gingival bleeding, heavy menstrual bleeding, and multiple post-operative hemorrhagic complications after previous surgeries. These complications included hemorrhagic compartment syndrome after an ankle surgery and bleeding complications with all three prior deliveries including persistent vaginal bleeding after her first two CDs and intra-abdominal hemorrhage after her third CD. Although she reported having had epidurals during her prior pregnancies, these anesthetic records were unavailable. Her family history is positive for mucocutaneous bleeding including maternal heavy menstrual bleeding and death of her maternal grandmother secondary to postpartum hemorrhage. Prior to this pregnancy, she was referred for evaluation of a bleeding disorder in advance of cervical spine surgery. Her extensive coagulation laboratory evaluation was unremarkable, including normal complete blood count and smear, activated partial thromboplastin time, prothrombin time, thrombin time, von Willebrand factor (VWF) parameters, fibrinogen activity, platelet aggregation studies (including ristocetin-induced platelet aggregation), platelet function assay, factor XIII level, and rotational thromboelastography. There was good documentation of her prior bleeding and no suspicion for other disorders, such as endocrine or connective tissue disorders. She was diagnosed with an unspecified inherited bleeding disorder. The differential diagnosis for her hemostatic defect included rare congenital bleeding disorders such as undetected VWF qualitative dysfunction or undetected defects in fibrin, fibrinolysis, or platelet function. She received prophylactic fresh frozen plasma (FFP), cryoprecipitate, platelets, and anti-fibrinolytic treatment as prophylaxis for her cervical spine surgery and achieved good hemostasis without complication.

Upon presentation for delivery, her laboratory values were unremarkable: hematocrit (Hct) 30%, platelets 169 × 10^3/ml, international normalized ratio (INR) 1.1, partial thromboplastin time (PTT) 30 s, fibrinogen activity 461 mg/dl, and a thromboelastogram (TEG) within normal parameters. Prior to her delivery, a multi-disciplinary care plan, including hematology, anesthesiology, and obstetric services was established and a delivery plan that balanced patient safety and birthing preferences agreed upon; contingency plans for transfusion and anatomic control of bleeding were in place in the event of obstetric hemorrhage. The risks and benefits of regional anesthesia in the setting of a unremarkable airway exam (Mallampati Score 2, normal head flexion and extension, and normal mouth opening), were discussed at length with the patient, acknowledging the diagnostic challenges and lack of a useful laboratory monitoring test.

The patient prophylactically received 2 units of FFP, 10 units of cryoprecipitate within 4 hours prior to CD, and 2 units of platelets immediately before the placement of her routine single shot spinal anesthetic (consisting of 12.5 mg hyperbaric bupivacaine, 10 mcg fentanyl, and 100 mcg preservative-free morphine). Following the delivery of a healthy infant, intravenous aminocaproic acid was immediately started and routine oxytocin was infused (at an approximate rate of 15 IU per hour). Poor uterine tone was noted after delivery, which improved after single dose of 200 ug IM methylergonovine and 800 mg buccal misoprostol administration. The estimated blood loss was 1.5 liters. In response to her higher-than-average blood loss, 2 additional units of platelets were given in the immediate postoperative period. Deep venous thrombosis prophylaxis consisted of sequential compression devices until ambulation; low molecular weight heparin was avoided. The patient was closely monitored for neuraxial hematoma. Her postoperative labs were notable for Hct 22%, platelets 175 × 10^3/ml, INR 1.1, PTT

Here, we present the anesthetic management and safe utilization of neuraxial anesthesia for a CD in a patient with an unspecified inherited bleeding disorder.

Introduction
Neuraxial anesthesia, which encompasses both spinal and epidural anesthesia, has been established as a safe and effective regional anesthetic technique for the obstetric patient. Although considered the standard of care for Cesarean deliveries (CDs), this technique carries a small but potentially devastating risk of neuraxial bleeding complications (e.g. spinal epidural hematomas (SEH)) that may result in significant neurological injury or compromise. The risk of SEH in obstetric patients from neuraxial anesthesia is estimated to be 1:168,0001. Parturients with coagulopathy or bleeding diathesis are at increased risk of neuraxial hematomas2–4. Although a recent study has provided a management outline for patients with unclassified bleeding disorders undergoing procedures5, no specific recommendations were made for CDs, which is unique in that hematologic management directly impacts anesthetic management. In fact, although parturients with known hemostatic deficiencies can often safely undergo neuraxial anesthesia once the hemostatic defects are corrected6–7, due to the lack of recommendations, neuraxial anesthesia is often avoided in these patients, as in patients with other coagulopathies8. Physiological hypercoagulability and larger lumbar epidural space during pregnancy may explain why SEH in parturients are rare. While older guidelines are more conservative regarding platelet count cutoffs for neuraxial anesthesia, the SEH risk in patients with platelet counts less than 70,000 remains unknown9.

Here, we present the anesthetic management and safe utilization of neuraxial anesthesia for a CD in a patient with an unspecified inherited bleeding disorder.

Case description
A 39-year-old G6P3 with an unspecified inherited bleeding disorder presented at 37-6/7 weeks gestational age for a fourth repeat scheduled CD in the setting of fetal macrosomia. The patient had a diagnosis of an unspecified bleeding disorder. Prior to diagnosis, her bleeding history consisted of easy bruising, gingival bleeding, heavy menstrual bleeding, and multiple post-operative hemorrhagic complications after previous surgeries. These complications included hemorrhagic compartment syndrome after an ankle surgery and bleeding complications with all three prior deliveries including persistent vaginal bleeding after her first two CDs and intra-abdominal hemorrhage after her third CD. Although she reported having had epidurals during her prior pregnancies, these anesthetic records were unavailable. Her family history is positive for mucocutaneous bleeding including maternal heavy menstrual bleeding and death of her maternal grandmother secondary to postpartum hemorrhage. Prior to this pregnancy, she was referred for evaluation of a bleeding disorder in advance of cervical spine surgery. Her extensive coagulation laboratory evaluation was unremarkable, including normal complete blood count and smear, activated partial thromboplastin time, prothrombin time, thrombin time, von Willebrand factor (VWF) parameters, fibrinogen activity, platelet aggregation studies (including ristocetin-induced platelet aggregation), platelet function assay, factor XIII level, and rotational thromboelastography. There was good documentation of her prior bleeding and no suspicion for other disorders, such as endocrine or connective tissue disorders. She was diagnosed with an unspecified inherited bleeding disorder. The differential diagnosis for her hemostatic defect included rare congenital bleeding disorders such as undetected VWF qualitative dysfunction or undetected defects in fibrin, fibrinolysis, or platelet function. She received prophylactic fresh frozen plasma (FFP), cryoprecipitate, platelets, and anti-fibrinolytic treatment as prophylaxis for her cervical spine surgery and achieved good hemostasis without complication.

Introduction
Neuraxial anesthesia, which encompasses both spinal and epidural anesthesia, has been established as a safe and effective regional anesthetic technique for the obstetric patient. Although considered the standard of care for Cesarean deliveries (CDs), this technique carries a small but potentially devastating risk of neuraxial bleeding complications (e.g. spinal epidural hematomas (SEH)) that may result in significant neurological injury or compromise. The risk of SEH in obstetric patients from neuraxial anesthesia is estimated to be 1:168,0001. Parturients with coagulopathy or bleeding diathesis are at increased risk of neuraxial hematomas2–4. Although a recent study has provided a management outline for patients with unclassified bleeding disorders undergoing procedures5, no specific recommendations were made for CDs, which is unique in that hematologic management directly impacts anesthetic management. In fact, although parturients with known hemostatic deficiencies can often safely undergo neuraxial anesthesia once the hemostatic defects are corrected6–7, due to the lack of recommendations, neuraxial anesthesia is often avoided in these patients, as in patients with other coagulopathies8. Physiological hypercoagulability and larger lumbar epidural space during pregnancy may explain why SEH in parturients are rare. While older guidelines are more conservative regarding platelet count cutoffs for neuraxial anesthesia, the SEH risk in patients with platelet counts less than 70,000 remains unknown9.
28 s, and fibrinogen activity 462 mg/dl. Additionally, TEG results during and after the CD remained normal. The patient continued intravenous aminocaproic acid therapy postpartum, and transitioned to oral tranexamic acid for 5 days. She had an uneventful recovery and was discharged 3 days after surgery. The case management timeline and dosing regimen are shown in Figure 1.

Discussion

This patient’s unspecified inherited bleeding disorder placed her at considerably increased risk of peripartum bleeding with risks compounded by fetal macrosomia, multiple prior CDs, and a personal history of obstetric hemorrhage in the absence of prophylaxis. Typically, for a well-defined bleeding disorder prophylaxis can be used with appropriate repletion of the respective pathway components. For patients with unspecified bleeding disorders, it is not possible to know if the hemostatic defect has been adequately corrected by the prophylaxis treatment options available. However, in this case her spine surgery history could inform an effective prophylaxis regimen. For both procedures, the goal was to seek balanced hemostatic replacement for a rare hemostatic defect that was clinically established but undetectable by laboratory testing. For her spine surgery cryoprecipitate was administered with the goal of modest replacement treatment of several exogenous coagulation factors (fibrinogen, FXIII, VWF), which were in her bleeding disorder differential diagnosis. The addition of VWF replacement or ddAVP/desmopressin was thought to confer more risk than benefit because no laboratory defect in VWF (qualitative or quantitative) was found to support a diagnosis of von Willebrand disease (VWD). Although there are rare qualitative VWF defects known to cause VWD that we cannot test for clinically, there remained other possible hemostatic defects in her differential diagnosis that VWF replacement would not correct. Conversely, there is a concern that a VWF infusion would result in unacceptably high levels of functional VWF, increasing her risk for thrombosis, as VWF is already markedly elevated by normal pregnancy.

We considered using ddAVP, not to correct a VWF defect, but to improve hemostasis in qualitative platelet disorders (which are in her differential diagnosis). However, ddAVP is rarely used unless there is an established laboratory response correcting a hemostatic defect, which is not the case here as her laboratory workup was normal. Specifically, for her spine surgery, ddAVP seemed suboptimal due to its short duration of action compared to the duration of hemostatic control needed after surgery. Similarly, for her delivery, ddAVP was not used because we already had a known, effective hemostatic regimen. Furthermore, even in established cases of type 1 VWD, ddAVP is used sparingly during delivery due to tachyphylaxis (ddAVP has a short effective treatment duration relative to the treatment duration needed to prevent postpartum hemorrhage) and increased risk for hyponatremia.

Good communication and detailed hematology recommendations regarding the type, dose, and timing of blood product administration were critical in the planning and delivery of a safe spinal anesthetic for this patient.

Despite the potential for prolonged duration of surgery in the setting of a fourth CD, a spinal anesthetic was preferred over a combined spinal epidural to minimize the risk of an epidural catheter-associated hematoma. Although spinal clonidine can extend anesthetic duration, it was not used because it can cause prolonged hypotension, potentially complicating patient management. General anesthesia, even with comparable safety in obstetrics, was reserved for a failed spinal anesthesia or bleeding emergency to optimize maternal uterine tone and fetal neurological adaptation, both of which are affected by the use of volatile anesthetics, and to allow for early maternal-infant skin-to-skin bonding, honoring the mothers wish. Also important, the patient desired a regional anesthetic.

Other management considerations to guide appropriate planning and reduce the risk of significant perioperative bleeding include: early pre-anesthetic consultation, pre-operative hematology consultation, expeditious use of intraoperative uterotonic, and maintenance of normothermia to prevent hypothermic coagulopathy. Co-loading with crystalloid or colloid prior to initiation of neuraxial anesthesia can attenuate hypotension—commonly observed with spinal-related sympathectomy—which may be...
exacerbated in the setting of acute hemorrhage. The use of non-steroidal anti-inflammatory drugs was avoided.

Since laboratory results, including TEG, did not reflect the patient’s hemostasis defect, close intraoperative monitoring of bleeding status was performed by continually evaluating vital signs, examining blood loss in the operative field and suction canisters, and closely communicating with the obstetricians about uterine tone. The above-average blood loss was attributed to uterine atony due to observation by the surgeons, though incomplete hemostasis could not be ruled out completely. Postoperatively, close neurological exams for 24 hours to monitor for clinical signs of SEH were performed, including motor function test of both legs every four hours. Additionally, the patient had been informed about common symptoms of SEH, including rapid onset of pain, new onset of radiculopathy, and sensory and motor deficits of her lower extremities. In the event of such signs and symptoms, an emergent neuraxial MRI would be performed.

In summary, this case report highlights the importance of a multi-disciplinary approach. Close communication and coordination between the hematology, obstetric, and obstetric anesthesiology services were crucial in achieving an uneventful CD in this patient with an otherwise extremely high bleeding risk.

Data availability
All data underlying the results are available as part of the article and no additional source data are required.

Consent
Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient.

Grant information
The author(s) declared that no grants were involved in supporting this work.

References

Open Peer Review

Current Peer Review Status: ✔️ ✔️

Version 2

Reviewer Report 05 December 2018

https://doi.org/10.5256/f1000research.18856.r41253

© 2018 Cobb B. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✔️ Benjamin G. Cobb
Department of Anesthesiology, University of North Carolina, Chapel Hill, NC, USA

The revised manuscript satisfactorily addresses all concerns described in my initial review.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 30 November 2018

https://doi.org/10.5256/f1000research.18856.r41252

© 2018 Lee A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✔️ Allison J. Lee
Department of Anesthesiology, Columbia University, New York City, NY, USA

The authors have satisfactorily addressed my concerns.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
The authors describe the use of regional anesthesia for cesarean section in a parturient with an unspecified inherited bleeding disorder. In this case, the clinical bleeding history in conjunction with the hematologic lab workup leading to the diagnosis of an ‘unspecified’ bleeding disorder is well described. The authors highlight both the importance of early multidisciplinary collaboration in the parturient with a bleeding disorder in an effort to minimize hemorrhagic complications. In addition, the role of informed consent for a patient with an unspecified bleeding disorder and unquantifiable risk of spinal/epidural hematoma should not be understated. Additional attention to the potential limitations of factor/platelet/fibrinogen replacement in the setting of qualitative coagulation defects to prevent hemorrhagic complications of neuraxial anesthesia may be warranted in the discussion. I commend the authors for describing the often challenging anesthetic risk-benefit assessment of a patient with an unspecified bleeding disorders.

- In addition to the cryoprecipitate transfusion, was von Willebrand factor/DDAVP administration considered given the unknown defect?
- Please clarify the institutional oxytocin protocol post-delivery.
- Following the postpartum hemorrhage, what guided the decision to transfuse two additional units of platelets postoperatively and not other factors/fibrinogen?
- Is there any published literature on the prevalence of ‘unspecified bleeding disorders’ and/or standardization of these clinical diagnoses in the setting of normal coagulation workups by hematologists?
- Please clarify post-operative neurologic monitoring plan, including nursing neurological check frequency and patient surveillance counseling (concerning signs/symptoms).

Is the background of the case's history and progression described in sufficient detail?
Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Partly

Is the case presented with sufficient detail to be useful for other practitioners?
Partly

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 06 Nov 2018

Laurent Bollag, University of Washington, Seattle, USA

Dear Dr. Cobb

Thank you for your comments to improve the quality of our manuscript. I will reply point by point to your comments:

- In addition to the cryoprecipitate transfusion, was von Willebrand factor/DDAVP administration considered given the unknown defect?
  Willebrand factor/DDAVP administration was not given based on the normal von Willebrand factor (VWF) parameters preoperatively.

- Please clarify the institutional oxytocin protocol post-delivery.
  Our protocol is as follows: 15 IU per hour given on a drip. Once adequate uterine tone is achieved, the dose is reduced to 7.5 IU per hour, and again, once the tone is reported to be adequate, reduced ca 50% (or 70ml/hr). This drip is continued postpartum.

- Following the postpartum hemorrhage, what guided the decision to transfuse two additional units of platelets postoperatively and not other factors/fibrinogen?
  While uterine atony was the likely reason for the PPH, incomplete hemostasis we assumed and platelet substitution deemed the most appropriate therapeutic first step.

- Is there any published literature on the prevalence of ‘unspecified bleeding disorders’ and/or standardization of these clinical diagnoses in the setting of normal coagulation workups by hematologists?
  The lack of such literature prompted this report.

- Please clarify post-operative neurologic monitoring plan, including nursing neurological check frequency and patient surveillance counseling (concerning signs/symptoms).
  Local guidelines include vigilant neurological checks, including motor function of both legs every 4 hours for 24 hours. Patients are informed about the common symptoms of spinal nerve compression and the need to urgently report these to the nursing staff, namely:
  1. rapid onset of pain
  2. new onset radiculopathy
  3. sensory and
  4. motor function deficits
An emergent lumbar MRI will then confirm the diagnosis.

**Competing Interests:** None
Partly

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Partly

Is the case presented with sufficient detail to be useful for other practitioners?
Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 06 Nov 2018
Laurent Bollag, University of Washigton, Seattle, USA

Dear Dr Lee
Thank you for taking the time to review our case report to improve its quality!
I addressed your comments point by point below:

I was curious about the airway exam, considering that the team would have to prepare the possibility of inducing general anesthesia. I wonder if consideration was given to administering DDAVP or other treatment for von Willebrand's disease. Was an arterial line placed or considered, and what was the intravenous access in place?

Her airway exam was as follows: Mallampati Score 2, free head and neck movement (>6cm), normal mouth opening and no prominent incisors, in short pretty normal.

Willebrand factor/DDAVP administration was not recommended by the hematologist based on the normal von Willebrand factor (VWF) parameters preoperatively.

She had a well working 18g IV. We decided not to place an Aline a priori, because we felt that it could be sited easily if need be. In cases where the placement is deemed technically complicated we do place A lines when a PPH is deemed likely, the same applies to a second large bore IV.

I am curious about the components of the intrathecal medications for the single shot spinal anesthetic. With the possibility for prolonged surgery, were any adjuvants, such as clonidine added to prolong the anesthetic?

We used out routine SPA mixture 12.5mg hyperbaric Bupivacaine, 10mcg Fentanyl and 100mcg PF Morphine. We did not add spinal clonidine, to avoid worsening of hypotension in a case where a PPH was deemed likely. Clonidine could also be added later IV, to extend spinal anesthesia duration, but again potentially worsen hypotension- for hours.
Obviously, we opted not to place a CSE in this potentially coagulopathic patient.

**Explain what is "routine oxytocin" in your institution. For what period postoperatively was the patient "closely monitored" and how? Were there nursing orders for frequent checks of neurologic status? Finally, I would suggest discussing the reasons for the low incidence of epidural hematoma in the obstetric population and including this reference: Lee L, et al.**

Physiological hypercoagulability of pregnancy as well as the large epidural space in young parturients may explain why epidural hematomas in parturients are rare; additionally older guidelines are more conservative regarding platelet count cut-offs for neuraxial anesthesia. The risk of performing neuraxial anesthesia in patients with platelet counts of less than 70,000 however remains unknown.  

We have addressed your other comments in our response to reviewer 1, who raised the same questions.

References

**Competing Interests:** None